ClinicalTrials.Veeva

Menu

Key Specialized Monitoring of Clinical Safety of Pudilan Xiaoyan Oral Liquid in the Real World

C

China Academy of Chinese Medical Sciences

Status

Unknown

Conditions

Respiratory Infectious Diseases

Treatments

Drug: Pudilan Xiaoyan Oral Liquid

Study type

Observational

Funder types

Other

Identifiers

NCT04031651
PUDILAN

Details and patient eligibility

About

To obtain the characteristics of adverse reactions/incidents, analyze the influencing factors and calculate the incidence of adverse reactions/incidents monitored by Pudilan Xiaoyan Oral Liquid in key specialties in the real world, so as to provide a basis for clinical safe and rational drug use.

Enrollment

10,000 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • (1)Upper respiratory tract infection patients using Pudilan antiphlogistic oral liquid ;
  • (2)Aged between 18 and 80.

Exclusion criteria

  • Lactating women, pregnant women, pregnant planners, psychiatric patients, etc.

Trial contacts and locations

0

Loading...

Central trial contact

Qing Miao, doctor; Yanming Xie, BA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems